Evaluating Bayesian Borrowing Methods for Treatment Effect Extrapolation: A Simulation-Based Study
At ISPOR Europe 2025, Marie Génin and Antoine Movschin presented Quinten Health’s large-scale simulation study assessing Bayesian borrowing methods for extrapolating treatment effects from a source population to a target population. These methods are particularly relevant in paediatrics, rare diseases, and small-population contexts where direct evidence generation is difficult. Poster presented by Marie and Antoine […]
Development of an AI-Powered Tool to Accelerate and Enhance Systematic Literature Reviews for Evidence-Based Decision-Making in Clinical Research
Accelerating Systematic Literature Reviews with an AI-Powered Screening Tool At ISPOR Europe 2025, Paul Loustalot from Quinten Health presented a new AI-powered tool designed to accelerate and enhance systematic literature reviews (SLRs) by semi-automating title and abstract screening. The tool enhances efficiency while preserving the scientific rigor required in evidence-based clinical research. Paul Loustalot presenting […]
Comparing Individualized Treatment Effect Inference Methods Through a Simulation Study
At ISPOR Europe 2025, Antoine Movschin presented Quinten Health’s simulation-based comparison of machine-learning approaches for estimating individualized treatment effects (ITE). As healthcare increasingly relies on real-world data and personalized medicine, robust estimation of patient-level treatment effects is essential for research, clinical practice, and HTA decision-making. Antoine Movschin presenting the poster at ISPOR Europe 2025. Why […]
An AI-Powered Tool to Identify and Assess Fit-for-Use Registries for Drug Development and Evaluation
At ISPOR Europe 2025, Quinten Health introduced an AI-powered tool, a deliverable of the More-EUROPA consortium, designed to make real-world data discovery faster, smarter, and more transparent, supporting regulators, HTA bodies, and researchers to identify, assess, and select fit-for-use registries for evidence generation across the drug and product development lifecycles. Leveraging AI to Identify and […]
A New Regulatory-Grade Chronic Disease Cohort Simulator: Leveraging the Large, Deep, and Long Constances Cohort Linked and Matched to the SNDS in France
Quinten Health presented at ISPOR Europe 2025 a new regulatory-grade chronic disease cohort simulator built from the CONSTANCES cohort linked and individually matched to the French SNDS. This unique data asset provides an unprecedented foundation for generating transparent, reproducible, and high-quality real-world evidence for HTA, regulatory assessment, and long-term disease modelling. Marie Génin presenting the […]
Evaluating Bayesian Borrowing Methods for Treatment Effect Extrapolation: A Simulation-Based Study
Event: ISPOR Europe 2025, Glasgow, Scotland, UK Authors: Marie Génin, Tristan Fauvel, Antoine Movschin, Billy Amzal View Poster OBJECTIVES Bayesian borrowing methods are increasingly used to extrapolate treatment effects when direct evidence generation is challenging, such as for pediatrics or rare diseases. This study aimed to evaluate and compare the performance of Bayesian methods for treatment […]
Development of an AI-Powered Tool to Accelerate and Enhance Systematic Literature Reviews for Evidence-Based Decision Making in Clinical Research
Event: ISPOR Europe 2025, Glasgow, Scotland, UK Authors: Paul Loustalot, Boris Kopin, Sacha Levy, Basile Ferry, Vincent Martenot View Poster OBJECTIVES Systematic literature reviews (SLRs) are foundational for evidence-based decisions-making across the pharmaceutical and medical devices product lifecycle, from early research and development to market launch, and post-market activities. Conventional SLRs are often time- and resource-intensive, […]
Comparing Individualized Treatment Effect Inference Methods Through a Simulation Study
Event: ISPOR Europe 2025, Glasgow, Scotland, UK Authors: Diane Vincent, Antoine Movschin, Tristan Fauvel View Poster OBJECTIVES Randomized controlled trials (RCTs) are the gold standard for estimating the average treatment effect (ATE), based on the equipoise principle and proper trial size and design, but they are typically not geared towards individual effect estimation. Conversely, real-world data […]
A New Regulatory-Grade Chronic Disease Cohort Simulator: Leveraging the Large, Deep, and Long Constances Cohort Linked and Matched to the SNDS in France
Event: ISPOR Europe 2025, Glasgow, Scotland, UK Authors: Marie Génin, Antoine Movschin, Sofiane Kab, Billy Amzal View Poster OBJECTIVES Virtual cohorts and synthetic patients are gaining traction to address data scarcity, privacy and ethical constraints in drug development. Quinten Health in partnership with INSERM/CONSTANCES, one of the largest general population cohorts in EU is developing a […]
An AI-Powered Tool to Identify and Assess Fit-for-Use Registries for Drug Development and Evaluation
Event: ISPOR Europe 2025, Glasgow, Scotland, UK Authors: Ghinwa Y. Hayek, Boris Kopin, Sonia Zebachi, Gaëtan Pinon, Basile Ferry, Elisabeth Bakker, Alexandre Macquin, Sieta T. de Vries, Peter G.M. Mol, Billy Amzal View Poster OBJECTIVES Selecting appropriate real-world data (RWD) sources, particularly registries, is a primary challenge for academia, industry, regulators, and health technology assessment (HTA) […]
